Retinosis pigmentaria

There is no population-wide screening program for RP. Targeted screening is recommended for all first-degree relatives of RP patients and for specific high-risk groups. The most important screening message is that early diagnosis—even before significant symptoms are noticed—creates crucial opportunities: it opens eligibility evaluation for Luxturna® in appropriate patients, allows treatment of preventable complications such as cataracts and macular edema before they cause irreversible additional damage, and enables early connection with genetic counseling and rehabilitation services while vision is still relatively well preserved.

The gold-standard test for detecting RP—including in people who have no symptoms and whose retinas appear entirely normal on examination—is the full-field electroretinogram (ERG). This test measures the electrical response of rod and cone photoreceptors to standardized light stimuli under both dark-adapted (rod-testing) and light-adapted (cone-testing) conditions. In RP, rod responses are dramatically reduced or absent before the retina looks abnormal on examination and before the patient has noticed meaningful visual symptoms. This early-detection advantage makes the ERG the test of choice for presymptomatic screening of all first-degree relatives of RP patients and for children under age 7 in whom visual field testing is unreliable. Additional screening tools used alongside the ERG include automated visual field testing (perimetry), dark adaptometry to detect early rod dysfunction, optical coherence tomography (OCT) to image retinal layers, and fundus autofluorescence to detect the boundary between surviving and degenerated photoreceptor areas. Once a causative mutation has been identified in an affected family member, genetic cascade testing—offering targeted mutation testing to relatives—is the most efficient and definitive screening approach.

The hallmark symptom of RP, and typically the first to appear, is night blindness, known medically as nyctalopia. Night blindness arises from dysfunction of the rod photoreceptors and may precede all other symptoms by years or even decades. Many patients delay seeking care because they attribute their difficulty in dim light to normal variation, because daytime vision remains entirely normal during early-stage disease, and because the gradual nature of the change makes it easy to overlook. The average age at formal diagnosis is approximately 35 years—meaning significant retinal degeneration has typically already occurred before most patients are identified and referred to a retinal specialist.

• Night blindness (nyctalopia): difficulty seeing in dim rooms, dark stairwells, movie theaters, or while driving after dark. Prolonged time required to adjust when moving from a bright environment into a dark one.
• Peripheral visual field defects in low light: Daylight peripheral vision may remain relatively intact in the early stage, but gaps develop in the peripheral visual field under dim conditions.
• Photopsia: —This is brief shimmering, flickering, or flashing lights perceived in the periphery, caused by abnormal electrical activity in degenerating photoreceptors.
• Subtle spatial misjudgments: This is occasionally stepping on objects or misjudging distances in low light without fully recognizing why.

• Progressive peripheral visual field loss in all conditions: The characteristic ring scotoma (a circular gap in the visual field) develops and gradually expands inward, producing the experience of tunnel vision. This affects both daylight and low-light vision.
• Photophobia: Hypersensitivity to diffuse bright light, including cloudy days and indoor fluorescent lighting, becomes a prominent and disabling symptom. Approximately 80% of RP patients in large European studies do not meet legal driving requirements at this stage.
• Dyschromatopsia: This is impaired color vision, particularly along the blue-yellow axis.
• Reduced visual acuity: This begins most commonly from posterior subcapsular cataract (present in about 43% of RP patients), cystoid macular edema (about 18%), or epiretinal membrane (about 51%)—all of which are partially treatable causes of additional central vision decline.
• Functional impairment: This includes missing handshakes, bumping into objects to the side, difficulty reading menus in dim restaurants, and loss of driving eligibility.
• Sleep disturbances: Up to 76% of RP patients develop sleep problems caused by disrupted circadian rhythms from reduced light input to the brain’s internal clock.

• Severe tunnel vision: The visual field is compressed to a small central island, making independent navigation in unfamiliar environments extremely difficult and raising the risk of falls and injuries.
• Central vision loss: Reading becomes impossible without powerful magnification; recognizing faces is impaired.
• Intense photophobia: This is sensitivity to all ambient light.
• Retained light perception: Even in end-stage RP, most patients retain some awareness of light and dark, which supports use of the Argus II Retinal Prosthesis System.

Retinitis pigmentosa is diagnosed by a retinal specialist, an ophthalmologist with subspecialty expertise in retinal diseases, using a combination of clinical examination, electrophysiological testing, imaging, and genetic analysis. Despite more than 75% of patients being symptomatic by age 30, the mean age at formal diagnosis is approximately 35 years, reflecting significant delays at the primary care and optometry level. When clinical diagnosis is established, genetic testing is the essential next step to define the inheritance pattern, counsel the family, and determine eligibility for Luxturna®.

The full-field ERG is the single most important test for diagnosing and staging RP. It measures the electrical response generated by photoreceptors and downstream retinal cells in response to standardized flashes of light under dark-adapted conditions (testing rods) and light-adapted conditions (testing cones). In RP, rod responses are dramatically reduced—often absent—before cone responses become affected, before the retina looks abnormal on examination, and before the patient reports significant symptoms. This makes ERG the only test capable of detecting RP at a presymptomatic stage. It is the test of choice for screening first-degree relatives of RP patients and for all children under age 7 in whom reliable visual field testing is not possible.

Automated visual field testing (Humphrey 24-2 or 30-2) and Goldmann kinetic perimetry map the extent and pattern of peripheral vision loss. They are the primary tools for monitoring disease progression over time and for documenting the rate of annual field loss (averaging 4–12% per year). RP produces a characteristic pattern: patchy peripheral scotomas that evolve into a ring scotoma and then progressive concentric constriction toward the center, producing the experience of tunnel vision.

Optical coherence tomography provides high-resolution cross-sectional images of every retinal layer, allowing measurement of photoreceptor outer segment length, outer nuclear layer thickness (the layer containing photoreceptor cell bodies), and integrity of the inner segment/outer segment junction—a key structural marker of photoreceptor health. OCT also detects cystoid macular edema, epiretinal membranes, and vitreomacular traction—all potentially treatable contributors to central vision loss. Serial OCT measurements track structural progression alongside functional ERG and perimetry data.

Fundus autofluorescence imaging uses a specialized camera to detect the natural fluorescence of lipofuscin—a metabolic byproduct that accumulates in the RPE. In RP, a characteristic ring of increased autofluorescence forms at the boundary between surviving and degenerated photoreceptors, corresponding closely to the edge of the preserved visual field. The area enclosed by this ring correlates with preserved vision, and the rate at which the ring contracts inward over time serves as a measure of disease progression. FAF is particularly useful for monitoring the structural response to treatments such as Luxturna®.

Comprehensive genetic testing—using next-generation sequencing panels targeting the most common RP genes, supplemented by whole exome or whole genome sequencing when panels are negative—is recommended for all confirmed RP patients. A molecular diagnosis is currently achieved in approximately 50% of cases, a rate that continues to improve with expanding panels and improved methods for interpreting genetic variants. Genetic testing is essential for determining inheritance pattern and counseling family members, identifying which relatives are carriers or at risk, guiding family planning decisions, and qualifying patients for Luxturna®—which requires confirmed biallelic RPE65 mutations by a validated genetic test before treatment can proceed.

There is currently no cure for RP for the vast majority of patients. The one exception is the 1–6% of patients with confirmed biallelic RPE65 mutations, for whom voretigene neparvovec-rzyl (Luxturna®) offers the first and only FDA-approved disease-modifying treatment for any inherited retinal dystrophy. For all other patients, treatment focuses on slowing photoreceptor degeneration, treating ocular complications that cause preventable additional vision loss, maximizing functional independence through optical and electronic aids, and supporting the significant psychological burden of progressive vision loss. A multidisciplinary team—retinal specialist, genetic counselor, low-vision specialist, orientation and mobility specialist, psychologist, and vocational rehabilitation counselor—provides the best outcomes for patients navigating this condition across its decades-long course.

Luxturna® (voretigene neparvovec-rzyl) was FDA-approved in December 2017 as the first gene therapy approved in the United States for any inherited disease and the first approved for any inherited retinal dystrophy.

Luxturna® is indicated for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy—meaning both copies of the RPE65 gene are non-functional—as may occur in certain forms of RP or in the related condition Leber congenital amaurosis (LCA). Patients must have sufficient surviving retinal cells confirmed on imaging to be eligible for treatment. This applies to approximately 1–6% of all RP patients—an estimated 1,000 to 2,000 Americans.

Luxturna® uses a harmless, engineered viral vector (adeno-associated virus serotype 2, or AAV2) carrying a functional copy of the RPE65 gene. This vector is injected directly beneath the retina (subretinal injection) in a surgical procedure. RPE cells take up the vector and begin producing functional RPE65 protein—restoring the visual cycle step that was absent because of the mutation. Both eyes are treated in separate sequential surgeries. In Phase 3 clinical trials, patients reported subjective vision improvements within one month of treatment, including the ability to navigate a mobility course at light levels that were previously impossible. Many patients described seeing stars for the first time. Benefits have been maintained at three or more years of follow-up. Reported side effects include temporary elevated intraocular pressure (18%), cataract (18%), and, in some cases, areas of retinal cell loss (chorioretinal atrophy) at the injection site.

Vitamin A palmitate at a dose of 15,000 international units (IU) per day orally is the most studied pharmacological intervention for RP. A landmark randomized controlled trial published in 1993 found that this dose significantly slowed the annual rate of ERG amplitude decline over 5 to 12 years compared to placebo. It is not FDA-approved specifically for RP and remains a topic of ongoing clinical debate. If vitamin A is prescribed, liver function tests, serum vitamin A levels, and triglycerides must be monitored regularly, because vitamin A is stored in the liver and can cause toxicity at high doses. Vitamin A is absolutely contraindicated in patients with ABCA4 gene mutations (in whom it accelerates disease), in pregnant women (teratogenic risk), in children, and in patients with liver disease. Importantly, vitamin E supplementation at 400 IU per day was found in the same landmark study to have adverse effects on ERG amplitude and should be avoided by RP patients. Docosahexaenoic acid (DHA, an omega-3 fatty acid at 1,200 mg per day) showed early promise as an add-on to vitamin A, but its benefit did not persist beyond two years and is not currently standard of care.

For cystoid macular edema—a treatable cause of additional central vision loss affecting approximately 18% of RP patients—the oral carbonic anhydrase inhibitor acetazolamide (Diamox, up to 500 mg per day) can reduce fluid accumulation during acute episodes. Topical carbonic anhydrase inhibitor eye drops (such as dorzolamide) have been shown to be less effective for the chronic CME pattern commonly seen in RP. Patients with persistent or worsening CME should be evaluated by a retinal specialist for the most appropriate individual approach.

Posterior subcapsular cataract—present in approximately 43% of RP patients—is treated with standard phacoemulsification cataract surgery and intraocular lens implantation. Even relatively mild lens opacities can cause substantial functional impairment in RP patients due to photophobia and a narrow tolerance for diffuse light scatter, so the threshold for offering surgery is lower than in the general population. Outcomes are generally favorable. The complication rate is somewhat higher than for the general cataract population, including elevated rates of posterior capsular opacification, cystoid macular edema after surgery, and zonular weakness. Careful macular OCT evaluation and thorough counseling are essential before surgery. For epiretinal membrane causing significant central vision distortion, vitrectomy with membrane peeling may benefit selected patients. For the pseudo-Coats reaction—large peripheral retinal exudates that can progress to retinal detachment, particularly in RP associated with CRB1 gene mutations—laser photocoagulation or cryotherapy is used to reduce exudates and prevent detachment.

The Argus II Retinal Prosthesis System received FDA approval in February 2013 for patients with end-stage RP who have bare light perception or worse in both eyes, are 25 years of age or older, and have a history of prior useful vision. The system converts video from a glasses-mounted camera into electrical signals that are wirelessly transmitted to a 60-electrode array surgically implanted on the retinal surface. The array stimulates surviving retinal ganglion cells—which persist long after photoreceptors are lost—generating perception of light patterns in the visual cortex. The device provides basic light-dark contrast and coarse form perception rather than high-resolution vision, but patients have demonstrated significant improvement on orientation and mobility tasks with the device active compared to inactive, with benefits maintained at five years of follow-up. Note that Second Sight Medical Products, the manufacturer of the system, commercially restructured around 2022 and has limited device availability. Patients with implants or those interested in the device should consult their vitreoretinal care team regarding current availability and support.

Low vision aids and assistive technologies are a central and evidence-based component of RP management at every disease stage. Optical aids include handheld and stand magnifiers, telescopic spectacles for distance tasks, bioptic telescopes, and reverse-telescope systems for expanding the functional visual field in tunnel vision. Electronic aids include desktop CCTV magnifiers, portable electronic magnifiers, and tablet-based magnification apps. Night vision devices—including infrared-enhanced goggles—provide meaningful help navigating in low-light conditions. UV-blocking wraparound sunglasses with lateral shields, photochromic lenses, and yellow-orange tinted glasses reduce photophobia and may slow phototoxic degeneration. Screen readers, text-to-speech software, and voice-activated technology maintain access to information as reading vision declines. Orientation and mobility training with a long white cane or guide dog provides critical independent navigation skills as peripheral field loss progresses.

Low-vision rehabilitation—delivered by a coordinated team including a low-vision optometrist, occupational therapist, orientation and mobility specialist, and vocational rehabilitation counselor—is among the most impactful interventions for preserving quality of life and independence in RP. Genetic counseling is a standard ongoing component of RP management, covering inheritance patterns, family member risk, reproductive planning options, and updates as new treatments become available. Psychological support—from a clinical psychologist familiar with chronic vision loss—is essential at key disease milestones, including the initial diagnosis, onset of driving restrictions, legal blindness, and loss of independent reading. Depression and anxiety are systematically elevated in RP patients and should be screened for at every clinic visit. Peer support organizations such as the Foundation Fighting Blindness (fightingblindness.org) provide community, access to current research updates, and information on clinical trial enrollment opportunities.